Activation of PXR causes drug interactions with Paxlovid in transgenic mice
Acta Pharmaceutica Sinica B, 2023 Paxlovid is a nirmatrelvir (NMV) and ritonavir (RTV) co-packaged medication used for the treatment of coronavirus disease 2019 (COVID-19). The active component of Paxlovid is NMV and RTV is a pharmacokinetic booster.
Junjie Zhu, Xiaochao, Aaron S Devanathan
exaly +3 more sources
Cost-effectiveness of Paxlovid in reducing severe COVID-19 and mortality in China
Frontiers in Public Health, 2023 ObjectivesTo assess the cost-effectiveness of Paxlovid in reducing severe COVID-19 and its associated morality, and to investigate the affordable price of Paxlovid in China.Materials and methodsUsing a Markov model, two interventions by Paxlovid ...
Weina Zhang +5 more
exaly +3 more sources
A Retrospective Observational Study on COVID-19 Patients Receiving Treatment with Nirmatrelvir/Ritonavir (PAXLOVID) [PDF]
Pulmonary TherapyIntroduction This study was undertaken in COVID-19 patients treated with and without Paxlovid™ (Paxlovid) in an outpatient setting to determine hospitalization from the community.
Mariam M. Murad +13 more
doaj +2 more sources
Frontiers in Medicine, 2022 ObjectiveTo evaluate the efficacy of Paxlovid in treating Chinese elder patients infected with SARS-CoV-2 omicron variants.Materials and methodsWe performed a non-randomized, controlled trial in Shanghai, China.
Weijie Zhong +11 more
exaly +3 more sources
Development and application of a UHPLC-MS/MS method for the simultaneous determination of firmonertinib and its main metabolite AST-5902 in rat plasma: a study on the in vivo drug interaction between firmonertinib and paxlovid [PDF]
Frontiers in PharmacologyDue to the potential occurrence of drug interactions, the combined application of firmonertinib and paxlovid carries a relatively high risk. Nevertheless, as of now, there has been no comprehensive research on the interaction between firmonertinib and ...
Peng-Fei Tang +5 more
doaj +2 more sources
Paxlovid in Kidney Failure: A Review [PDF]
MPI (Media Pharmaceutica Indonesiana)The COVID-19 virus caused a global pandemic that claimed many lives. Various vaccines and drugs are used for COVID-19 both via intravenous and oral routes.
Ardianty, Nonie +2 more
core +3 more sources
A cost-effectiveness analysis of Molnupiravir and Paxlovid for outpatient treatment of COVID-19 in three African countries [PDF]
Journal of Public Health in AfricaBackground: Two COVID-19 oral antivirals (COAVs), Molnupiravir and Paxlovid, have been shown to be cost-effective in high-income countries. Aim: This study assesses the cost-effectiveness of Paxlovid and Molnupiravir, compared to usual care in three ...
Ijeoma P. Edoka +8 more
doaj +2 more sources
Paxlovid for the treatment of severe or critical COVID-19 in children [PDF]
BMC PediatricsBackground Paxlovid, known for its efficacy against SARS-CoV-2, is currently limited in its use for treating pediatric COVID-19, particularly in severe or critical cases.
Linjuan Xiang +15 more
doaj +2 more sources
European Journal of Case Reports in Internal Medicine, 2022 Tacrolimus is commonly used as a prophylactic against acute rejection in transplant patients. Tacrolimus toxicity has numerous presentations that have been well documented in the literature and can be induced by a wide variety of agents.
Aaisha Shah +3 more
doaj +3 more sources
Efficacy and safety of azvudine versus nirmatrelvir/ritonavir in cancer patients with COVID-19 [PDF]
Scientific ReportsCancer significantly contributes to the unfavorable prognosis of coronavirus disease 2019 (COVID-19) patients. The efficacy and safety of azvudine and nirmatrelvir/ritonavir (Paxlovid) in cancer patients with COVID-19 remain uncertain.
Bohan Jia +15 more
doaj +2 more sources